Table 2.
Baseline demographic characteristics for children in EBL2002, EBL2004, and EBL3001 stage 2 (per-protocol analysis set).a
| Study | Adolescentsb |
Older childrenc |
Younger childrend |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Age, years |
Sex, n (%)e |
N | Age, years |
Sex, n (%)e |
N | Age, years |
Sex, n (%)e |
||||
| Median (IQR) | Male | Female | Median (IQR) | Male | Female | Median (IQR) | Male | Female | ||||
| EBL2002 | ||||||||||||
| Vaccine | 53 | 14.0 (13.0; 15.0) | 29 (55) | 24 (45) | 54 | 8.0 (6.0; 10.0) | 26 (48) | 28 (52) | NA | NA | NA | NA |
| Burkina Faso | 29 | 14.0 (13.0; 16.0) | 19 (66) | 10 (34) | 23 | 8.0 (6.0; 9.0) | 11 (48) | 12 (52) | NA | NA | NA | NA |
| Côte d’Ivoire | 0 | – | – | – | 12 | 6.5 (4.0; 8.0) | 7 (58) | 5 (42) | NA | NA | NA | NA |
| Kenya | 12 | 13.5 (13.0; 15.0) | 5 (42) | 7 (58) | 5 | 8.0 (7.0; 10.0) | 2 (40) | 3 (60) | NA | NA | NA | NA |
| Uganda | 12 | 13.5 (12.5; 14.5) | 5 (42) | 7 (58) | 14 | 10.0 (6.0; 10.0) | 6 (43) | 8 (57) | NA | NA | NA | NA |
| Control | 10 | 14.0 (12.0; 16.0) | 6 (60) | 4 (40) | 11 | 7.0 (6.0; 9.0) | 6 (55) | 5 (45) | NA | NA | NA | NA |
| Burkina Faso | 4 | 16.0 (15.0; 16.5) | 3 (75) | 1 (25) | 4 | 7.5 (7.0; 8.0) | 2 (50) | 2 (50) | NA | NA | NA | NA |
| Côte d’Ivoire | 0 | – | – | – | 2 | 6.0 (5.0; 7.0) | 1 (50) | 1 (50) | NA | NA | NA | NA |
| Kenya | 2 | 12.0 (12.0; 12.0) | 0 | 2 (100) | 1 | 9.0 (9.0; 9.0) | 1 (100) | 0 | NA | NA | NA | NA |
| Uganda | 4 | 14.0 (13.0; 14.5) | 3 (75) | 1 (25) | 4 | 8.0 (5.5; 10.5) | 2 (50) | 2 (50) | NA | NA | NA | NA |
| EBL2004 | ||||||||||||
| Vaccine | 132 | 14.0 (13; 16) | 80 (61) | 52 (39) | 112 | 8.0 (6; 9) | 58 (52) | 54 (48) | 110 | 3.0 (2; 4) | 50 (46) | 60 (55) |
| Guinea | 42 | 14.5 (13.0; 16.0) | 25 (60) | 17 (41) | 53 | 7.0 (6.0; 9.0) | 27 (51) | 26 (49) | 57 | 3.0 (2.0; 3.0) | 26 (46) | 31 (54) |
| Liberia | 24 | 13.5 (12.0; 15.0) | 14 (58) | 10 (42) | 14 | 7.5 (5.0; 8.0) | 6 (43) | 8 (57) | 5 | 1.0 (1.0; 3.0) | 1 (20) | 4 (80) |
| Mali | 22 | 15.0 (13.0; 16.0) | 11 (50) | 11 (50) | 20 | 8.0 (6.5; 10.0) | 14 (70) | 6 (30) | 38 | 3.0 (2.0; 4.0) | 19 (50) | 19 (50) |
| Sierra Leone | 44 | 14.0 (13.0; 16.0) | 30 (68) | 14 (32) | 25 | 9.0 (7.0; 10.0) | 11 (44) | 14 (56) | 10 | 3.0 (2.0; 4.0) | 4 (40) | 6 (60) |
| Control | 55 | 15.0 (13; 16) | 30 (55) | 25 (46) | 54 | 8.0 (6; 9) | 30 (56) | 24 (44) | 49 | 3.0 (2; 4) | 23 (47) | 26 (53) |
| Guinea | 24 | 15.0 (13.0; 15.0) | 12 (50) | 12 (50) | 20 | 7.0 (6.0; 9.0) | 11 (55) | 9 (45) | 24 | 2.0 (1.5; 4.0) | 12 (50) | 12 (50) |
| Liberia | 8 | 15.0 (13.5; 15.5) | 6 (75) | 2 (25) | 9 | 8.0 (5.0; 9.0) | 6 (67) | 3 (33) | 1 | 2.0 (2.0; 2.0) | 0 | 1 (100) |
| Mali | 7 | 13.0 (12.0; 15.0) | 2 (29) | 5 (71) | 9 | 9.0 (8.0; 10.0) | 3 (33) | 6 (67) | 18 | 3.0 (2.0; 3.0) | 7 (39) | 11 (61) |
| Sierra Leone | 16 | 15.5 (13.0; 16.5) | 10 (63) | 6 (38) | 16 | 7.0 (6.0; 9.0) | 10 (63) | 6 (38) | 6 | 2.5 (2.0; 3.0) | 4 (67) | 2 (33) |
| EBL3001 stage 2 | ||||||||||||
| Vaccine | 142 | 14.0 (13.0; 16.0) | 74 (52) | 68 (48) | 134 | 8.0 (7.0; 9.0) | 64 (48) | 70 (52) | 126 | 2.0 (1.0; 3.0) | 72 (57) | 54 (43) |
| Control | 46 | 13.5 (13.0; 15.0) | 25 (54) | 21 (46) | 45 | 8.0 (7.0; 9.0) | 20 (44) | 25 (56) | 41 | 2.0 (1.0; 3.0) | 24 (59) | 17 (41) |
IQR; Interquartile range, NA; Not applicable.
a
Body-mass index was not included as it is not a reliable reflection of growth index in children below 12 years of age.
b
Participants aged 12–17 years in EBL2002, EBL2004, and EBL3001 stage 2.
c
Participants aged 4–11 years in EBL2002 and EBL3001 stage 2 and 5–11 years in EBL2004.
d
Participants aged 1–4 years in EBL2004 and 1–3 years in EBL3001 stage 2.
e
Percentages may not add up to 100 due to rounding.